Ascentage Pharma posted its 2026 interim report on September 17, 2026, covering financial highlights, Business highlights and interim financial statements. Investors can also review management discussion, an independent review report and other information included in the interim announcement.

Key Highlights

  • The report describes the 2023 placing as involving 22,500,000 Shares at HK$24.45 per share.
  • Ascentage Pharma Group International is a biotechnology company.
  • Each ADS represents 4 Ordinary Shares under the report’s definitions.

Interim Report Covers Financial and Business Updates

Ascentage Pharma Group International is a biotechnology company. The report is structured around corporate information, financial highlights, business highlights, management discussion and analysis, and other information. It also contains an independent review report and interim consolidated statements covering profit or loss, comprehensive income or loss, financial position, changes in Equity and cash flows. The document also includes definitions for terms used across Ascentage Pharma’s reporting. Those definitions cover the company, its subsidiaries, share schemes, placing arrangements, products and financial reporting terminology.

Historical Share Transactions Listed

It also describes the 2023 placing as involving 22,500,000 Shares at HK$24.45 per share. The 2025 placing is defined as a placing and subscription of 22,000,000 Shares at HK$68.60 each.